AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22233415
Drug: Thymosin alpha-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin alpha-1 1.6 mg SC twice weekly for 48 weeks
Trial: 22233415
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (peginterferon alfa-2a 180 mg/week with RBV 800-1200 mg/daily)
Trial: 17570054
Drug: Behaviorally-modified dental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behaviorally-modified dental intervention (splint therapy) using an interocclusal appliance worn up to 20 hours per day for 4 weeks.
Trial: 16262733
Drug: Daily self-administered
RxNorm normalized name: DAILY SELF DISCOVERY SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily self-administered 6-month regimen of rifampicin and isoniazid
Trial: 16262733
Drug: Twice-weekly, directly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly, directly observed 6-month regimen of rifampicin and isoniazid plus pyrazinamide for the first 2 months
Trial: 10440436
Drug: Ampicillin/sulbactam (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin/sulbactam (150 to 300 mg/kg/day in divided doses every 6 hours)
Trial: 10440436
Drug: Cefuroxime (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime (50 to 100 mg/kg/day in divided doses every 6 or 8 hours)
Trial: 7758054
Drug: NIF CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIF CC 30 mg daily with food
Trial: 7758054
Drug: NIF GITS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIF GITS 30 mg daily with food
Trial: 7758054
Drug: NIF CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIF CC
Trial: 28905108
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg/day, days 1-21)
Trial: 28905108
Drug: S-1 (80-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 (80-120 mg/day, days 1-14)
Trial: 26738328
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Tamsulosin at 0.2 mg qd plus Xipayimaizipizi at 0.5 g tid)
Trial: 26738328
Drug: Control (Tamsulosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Tamsulosin at 0.2 mg qd)
Trial: 20964867
Drug: Monthly oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly oral ibandronate (150 mg)
Trial: 15203552
Drug: Clarithromycin 250
RxNorm normalized name: clarithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 250 mg every other day orally
Trial: 11593074
Drug: Fluvoxamine, Clomipramine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine, Clomipramine, Citalopram, Paroxetine (standardized treatment over 12 weeks)
Trial: 25671925
Drug: Intravenous Morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Morphine 0.1mg/kg and Intravenous lidocaine 1.5 mg/kg
Trial: 25671925
Drug: Intravenous Morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Morphine 0.1mg/kg and lidocaine spray 1.5 mg/kg
Trial: 24231018
Drug: Higher-protein diet
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-protein diet (HP: 32% protein; 12.2 mg/day iron; 11.7 mg/day zinc)
Trial: 24231018
Drug: Lower-protein diet
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-protein diet (LP: 20%; 9.9 mg/day iron; 7.6 mg/day zinc) with >=10% weight loss
Trial: 20121898
Drug: L-arginine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (3 g three times daily)
Trial: 20121898
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 g three times daily)
Trial: 19216279
Drug: Implant-supported removable
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-supported removable partial denture (ISRPD)
Trial: 12668989
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid solution (75 g)
Trial: 10376778
Drug: Pistachio nuts
RxNorm normalized name: Pistachio nuts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pistachio nuts (20% of daily caloric intake)
Trial: 6370438
Drug: 0.05% diflorasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% diflorasone diacetate ointment in a vehicle of propylene glycol (PG)
Trial: 19784470
Drug: 0.05% clobetasol
RxNorm normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% clobetasol propionate ointment
Trial: 29929610
Drug: Double volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double volume saline (2 ml/kg/h for 12 h before and after the procedure)
Trial: 29929610
Drug: Standard volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard volume saline (1 ml/kg/h for 12 h before and after the procedure)
Trial: 24528614
Drug: Oral rapamycin
RxNorm normalized name: kanamycin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rapamycin plus bare-metal stent (OR)
Trial: 20232758
Drug: Oral simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral simvastatin (40 mg/d) plus topical betamethasone (50% in petrolatum) for 8 weeks
Trial: 20232758
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo plus topical betamethasone (50% in petrolatum) for 8 weeks
Trial: 15050090
Drug: Family cognitive‐behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family cognitive‐behavioral therapy
Trial: 15050090
Drug: Individual cognitive‐behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual cognitive‐behavioral therapy
Trial: 9734756
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation 1.5 mg/kg for 15 days
Trial: 9734756
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation 6.0 mg/kg for 15 days
Trial: 9734756
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation 6.0 mg/kg for 30 days
Trial: 7520659
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) treatment
Trial: 4919024
Drug: Amantadine 100
RxNorm normalized name: amantadine 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine 100 mg twice a day
Trial: 17509689
Drug: Intravitreal pegaptanib
RxNorm normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravitreal pegaptanib sodium (1 mg or 3 mg) every 6 weeks for 54 weeks
Trial: 15632883
Drug: Coumadin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coumadin plus aspirin
Trial: 28600024
Drug: Cilostazol plus
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol plus aspirin
Trial: 9820393
Drug: Self-reported rectal
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported rectal bleeding
Trial: 9820393
Drug: Self-reported rectal
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported rectal bleeding (blood on wiping)
Trial: 9820393
Drug: Self-reported rectal
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported rectal bleeding (blood coating stools)
Trial: 9820393
Drug: Self-reported rectal
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported rectal bleeding (dark blood mixed in stools)
Trial: 8575676
Drug: Gyno-Pevaryl 150
RxNorm normalized name: econazole nitrate Topical Powder [Pevaryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gyno-Pevaryl 150 treatment
Trial: 8575676
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (without G-P 150 treatment)
Trial: 2234646
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aspirin therapy
Trial: 2234646
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy or research in pregnancy
Trial: 685753
Drug: Aspirin, 1200
RxNorm normalized name: Aspirin, 1200 mg rectal suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, 1200 mg/day
Trial: 685753
Drug: Aspirin +
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin + Sulfinpyrazone
Trial: 28245383
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment group (hydroxyurea plus IFN‐α)
Trial: 28245383
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment group (hydroxyurea)
Trial: 22985776
Drug: Intensity-modulated radiotherapy
RxNorm normalized name: California intense cedar pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensity-modulated radiotherapy plus chemotherapy (IMRT-C)
Trial: 17672073
Drug: Nimesil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesil (200 mg/day)
Trial: 17672073
Drug: Aponil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aponil (200 mg/day)
Trial: 17672073
Drug: Sodium diclofenac
RxNorm normalized name: Diclofenac Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium diclofenac (150 mg/day)
Trial: 343226
Drug: Plain acetylsalicylic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain acetylsalicylic acid (ASA) tablet
Trial: 343226
Drug: Microencapsulated acetylsalicylic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microencapsulated acetylsalicylic acid (ASA) tablet
Trial: 343226
Drug: Control examinations
RxNorm normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control examinations (before ASA treatment)
Trial: 28605879
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (Enoxaparin) alone
Trial: 28605879
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (Enoxaparin followed by Rivaroxaban)
Trial: 23470649
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) 2 g/kg total dose (400 mg/kg per day for 5 days)
Trial: 23470649
Drug: Anti-D immunoglobulin
RxNorm normalized name: Anti-D immunoglobulin
DrugBank: Human Rho(D) immune globulin (DB11597)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-D immunoglobulin 50 μg/kg
Trial: 23470649
Drug: Anti-D immunoglobulin
RxNorm normalized name: Anti-D immunoglobulin
DrugBank: Human Rho(D) immune globulin (DB11597)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-D immunoglobulin 75 μg/kg
Trial: 10211920
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg daily plus pindolol 7.5 mg daily
Trial: 10211920
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg daily plus mianserin 30 mg daily
Trial: 1860197
Drug: Aspirin 325
RxNorm normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 325 mg preoperatively
Trial: 7046498
Drug: Etomidate (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate (0.1 mg/kg) preceded by diazepam (0.1 mg/kg)
Trial: 20463100
Drug: Calcium (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1200 mg daily) plus placebo
Trial: 24064695
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (100 μg) plus placebo
Trial: 12767658
Drug: Juice Plus
RxNorm normalized name: Nutritional Supplement Oral Liquid [JUICE PLUS WITH FIBER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Juice Plus (JP) and Vineyard (V) combination
Trial: 12767658
Drug: Juice Plus
RxNorm normalized name: Nutritional Supplement Oral Liquid [JUICE PLUS WITH FIBER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Juice Plus (JP) and Vineyard (V) combination and JP alone
Trial: 10694785
Drug: High flavonols
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High flavonols diet (77.3 mg/day or 110.4 mg/day)
Trial: 8218961
Drug: Celaskon 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celaskon 60 mg (CK60)
Trial: 8218961
Drug: Celaskon 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celaskon 500 mg (CK500)
Trial: 28903787
Drug: Metacognitive methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metacognitive methods combined with habit reversal therapy (MCT/HRT)
Trial: 15816634
Drug: Complementary administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Complementary administration of standardized mistletoe extract (Iscador)
Trial: 14676074
Drug: Rofecoxib (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (up to 37.5 mg)
Trial: 14676074
Drug: Celecoxib (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (up to 300 mg)
Trial: 14676074
Drug: Aspirin (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (up to 500 mg)
Trial: 14676074
Drug: Aspirin-induced urticaria
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin-induced urticaria
Trial: 1863024
Drug: pH‐sensitive, polymer‐coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pH‐sensitive, polymer‐coated oral preparation of mesalamine 2.4 g/d
Trial: 1863024
Drug: pH‐sensitive, polymer‐coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pH‐sensitive, polymer‐coated oral preparation of mesalamine 1.6 g/d
Trial: 25259747
Drug: Bedtime administration
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime administration of antihypertensive drugs
Trial: 22959763
Drug: Corticotropin-releasing hormone
RxNorm normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticotropin-releasing hormone
Trial: 19665364
Drug: Ephedrine 6
RxNorm normalized name: pseudoephedrine 6 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 6 mg (group E)
Trial: 16079222
Drug: Intraduodenal glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraduodenal glucose infusion (3 kcal/min) with guar gum (4 g)
Trial: 24525810
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg daily)
Trial: 1321037
Drug: Propofol (LD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (LD 2 mg kg‐1 and MD 6 mg kg‐1 h‐1)
Trial: 1321037
Drug: Etomidate (LD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate (LD 0.3 mg kg‐1 and MD 0.6 mg kg‐1 h‐1)
Trial: 1321037
Drug: Midazolam (LD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (LD 0.2 mg kg‐1 and MD 0.120 mg kg‐1 h‐1)
Trial: 1321037
Drug: Methohexitone (LD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methohexitone (LD 1.5 mg kg‐1 and MD 4 mg kg‐1 h‐1)
Trial: 1321037
Drug: Dehydrobenzperidol (0.05-0.23
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dehydrobenzperidol (0.05-0.23 mg kg‐1) and alfentanil (LD 0.100 mg kg‐1 and MD 0.060 mg kg‐1 h‐1)
Trial: 6547878
Drug: pindolol, 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pindolol, 15 mg daily
Trial: 6547878
Drug: hydrochlorothiazide, 50
RxNorm normalized name: HydroCHLOROthiazide, 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydrochlorothiazide, 50 mg daily
Trial: 6547878
Drug: both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: both drugs combined
Trial: 25354407
Drug: Podiatric treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Podiatric treatment
Trial: 18991037
Drug: Latanoprost 0.005%
RxNorm normalized name: LATANOPROST 0.005% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost 0.005% monotherapy for 12 weeks
Trial: 18991037
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Latanoprost 0.005% and Nipradilol 0.25% after 12 weeks
Trial: 18991037
Drug: Nipradilol 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nipradilol 0.25% monotherapy for 12 weeks
Trial: 18991037
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Nipradilol 0.25% and Latanoprost 0.005% after 12 weeks
Trial: 12017304
Drug: Post-operative adjuvant
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative adjuvant chemotherapy including mitomycin, anthracyclines, cyclophosphamide, alkylating agents, and 5-fluorouracil
Trial: 12017304
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with mitomycin, 5-fluorouracil and non-specific immunomodulators (PSK and OK-432)
Trial: 12017304
Drug: Post-operative adjuvant
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative adjuvant chemotherapy or immunochemotherapy
Trial: 9718288
Drug: Cotinine fumarate
RxNorm normalized name: Chinine
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cotinine fumarate 40 mg
Trial: 9718288
Drug: Cotinine fumarate
RxNorm normalized name: Chinine
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cotinine fumarate 80 mg
Trial: 9718288
Drug: Cotinine fumarate
RxNorm normalized name: Chinine
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cotinine fumarate 160 mg
Trial: 7917540
Drug: vindesine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vindesine (3 mg/m2/week) plus interferon-alpha 2b (6 U/m2 3 times per week)
Trial: 2523921
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of cromoglycate (C)
Trial: 3902672
Drug: Timolol 10
RxNorm normalized name: timolol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 10 mg twice daily
Trial: 7034470
Drug: Timolol 5
RxNorm normalized name: timolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 5 mg
Trial: 20009091
Drug: Monthly care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly care coordination telephone call (CC group)
Trial: 16037156
Drug: Ganoderma lucidum
RxNorm normalized name: GANODERMA LUCIDUM STEM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganoderma lucidum capsules 1.5 g daily for 4 weeks
Trial: 10687910
Drug: 1‐mg increments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1‐mg increments of midazolam at 1‐min intervals
Trial: 10687910
Drug: 0.1‐mg increments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1‐mg increments of midazolam without a lock‐out interval
Trial: 1725892
Drug: Oral nicardipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nicardipine (3 x 30 mg)
Trial: 31610637
Drug: Caffeine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6 mg/kg body weight via 12 ounces of coffee)
Trial: 27618781
Drug: Percutaneous radiofrequency
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous radiofrequency coagulation of the facet joint capsule
Trial: 20591628
Drug: Metformin (MET)
RxNorm normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (MET) 1000 mg/day for 14 weeks
Trial: 17266067
Drug: Mindfulness-Based Stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Stress Reduction (MBSR), 8-week intervention, 2.5-hour sessions weekly, led by a licensed clinical psychologist.
Trial: 12764515
Drug: Praziquantel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (60 mg/kg per day for three consecutive days)
Trial: 12764515
Drug: Oxamniquine (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxamniquine (two daily doses of 10 mg/kg)
Trial: 10600424
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of ascorbic acid supplementation per day
Trial: 10600424
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of ascorbic acid supplementation per day
Trial: 8763515
Drug: Alteplase (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase (100 mg over 3 hours)
Trial: 1663571
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated estrogens (Premarin)
Trial: 1663571
Drug: Micronized oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized oral progesterone